Skip to main content
. 2023 May 24;7(16):4302–4314. doi: 10.1182/bloodadvances.2023009903

Table 3.

IME indications and phase of development

Indication Phase of development Ongoing trials?
MDS Phase 2 (high risk), phase 3 (low risk) Yes
MF Phase 3 Yes
ET Phase 2 No
MM Phase 2, limited by clinical hold No
AML Phase 2 Yes
Lymphoid malignancies Planned No

MM, multiple myeloma.